Biomarkers of Nutritional Metabolic Stress During Hospitalization

Abstract

Hospitalization is a period often marked by acute metabolic stress, profoundly impacting nutritional status and clinical outcomes. The identification and interpretation of biomarkers reflecting nutritional metabolic stress are pivotal in guiding early intervention, risk stratification, and monitoring of hospitalized patients. This review discusses the current landscape of biomarkers relevant to nutritional metabolic stress, with an emphasis on their pathophysiological basis, clinical utility, and integration into evidence-based practices for improved patient care.

Introduction

The metabolic response to illness and injury during hospitalization is characterized by complex alterations in nutrient metabolism, hormonal regulation, and inflammatory pathways. These changes frequently precipitate or exacerbate nutritional deficits, leading to increased morbidity and mortality. Accurate assessment of nutritional metabolic stress through reliable biomarkers is crucial for timely diagnosis and management, particularly in critically ill and medically complex patients. This article reviews key biomarkers, their underlying mechanisms, and their application in clinical settings, synthesizing recent evidence to inform practice among healthcare professionals.

Epidemiology / Disease Burden

Nutritional metabolic stress is prevalent among hospitalized patients, especially those admitted to intensive care units (ICUs), surgical wards, and oncology units. Estimates suggest that up to 40% of hospitalized adults are at risk for malnutrition, with higher rates observed in the critically ill. Malnutrition and metabolic derangement during hospitalization are associated with prolonged length of stay, increased complications, greater healthcare costs, and higher mortality. The burden is particularly significant in elderly populations and those with chronic diseases, underscoring the need for efficient identification and monitoring strategies leveraging robust biomarkers.

Pathophysiology

The pathophysiology of nutritional metabolic stress is multifactorial, involving a dynamic interplay between catabolic and anabolic processes. Acute illness triggers neuroendocrine and inflammatory responses, leading to increased secretion of stress hormones (e.g., cortisol, catecholamines) and pro-inflammatory cytokines (e.g., IL-6, TNF-α). These mediators promote protein catabolism, insulin resistance, altered energy expenditure, and impaired nutrient utilization. Concurrently, organ dysfunction (hepatic, renal, gastrointestinal) further disrupts metabolic homeostasis, amplifying the risk for malnutrition and related complications. Biomarkers reflecting these processes serve as valuable indicators of metabolic stress severity and trajectory.

Risk Factors

Several patient- and illness-related factors predispose individuals to nutritional metabolic stress during hospitalization. Advanced age, pre-existing malnutrition, chronic comorbidities (such as diabetes, CKD, chronic liver disease), polypharmacy, and the severity of acute illness are well-established risk factors. Surgical interventions, sepsis, trauma, and cancer therapies further heighten metabolic demands and exacerbate nutrient losses. Recognizing these risk factors is essential for targeted screening and early biomarker-based assessment in high-risk patient groups.

Clinical Features

Clinical manifestations of nutritional metabolic stress are often subtle and nonspecific, including weight loss, muscle wasting, fatigue, poor wound healing, and increased susceptibility to infections. Laboratory abnormalities such as hypoalbuminemia, lymphopenia, and electrolyte disturbances may provide indirect evidence but lack specificity for acute metabolic stress. Therefore, reliance on objective biomarkers is increasingly advocated to allow for earlier detection and more precise assessment of metabolic derangements in hospitalized patients.

Diagnosis

Diagnosis of nutritional metabolic stress hinges on the integration of clinical evaluation with biomarker analysis. Traditional markers such as serum albumin and prealbumin have limitations, particularly in acute inflammatory states. Recent advances highlight the utility of C-reactive protein (CRP), interleukin-6 (IL-6), transthyretin, retinol-binding protein, and urinary urea nitrogen as dynamic indicators of metabolic stress and catabolism. Additionally, tools like the Nutrition Risk in the Critically Ill (NUTRIC) score incorporate biomarker data to enhance prognostic accuracy. Emerging metabolomic and proteomic approaches offer promise for more comprehensive assessment but require further validation.

Treatment & Management

Management strategies for nutritional metabolic stress prioritize early identification, individualized nutritional support, and modulation of the underlying metabolic response. Initiating enteral or parenteral nutrition tailored to caloric and protein requirements, alongside micronutrient supplementation, is central to therapy. Monitoring biomarker trends guides therapeutic adjustments and facilitates timely escalation or de-escalation of interventions. Addressing modifiable risk factors, optimizing glycemic control, and minimizing iatrogenic complications are also critical components of comprehensive care.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advancements in the identification and clinical integration of novel biomarkers. Proteins such as fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) have emerged as markers of metabolic stress and mitochondrial dysfunction. The application of metabolomic profiling enables the detection of nuanced changes in amino acid, lipid, and energy metabolism. Non-invasive technologies, including point-of-care testing and continuous metabolic monitoring, are being developed to facilitate real-time assessment and intervention. Furthermore, targeted therapies aiming to modulate the metabolic and inflammatory response to stress are under investigation, potentially transforming the landscape of nutritional management in hospitalized patients.

Guideline Recommendations

Current clinical guidelines from organizations such as the European Society for Clinical Nutrition and Metabolism (ESPEN) and the American Society for Parenteral and Enteral Nutrition (ASPEN) advocate for routine screening of nutritional risk and the use of validated biomarkers where available. Early and systematic nutritional assessment is recommended for all hospitalized patients, with particular attention to those in ICUs or at high risk for metabolic complications. Biomarkers should be interpreted in the context of the overall clinical picture, with multidisciplinary collaboration to optimize care. Ongoing research is expected to refine these recommendations as novel biomarkers and therapeutic strategies become more widely available.

Conclusion

Biomarkers of nutritional metabolic stress represent essential tools in the management of hospitalized patients, enabling early detection, risk stratification, and tailored nutritional interventions. Advances in biomarker discovery and technology are enhancing the precision and efficiency of clinical assessment, with the potential to improve patient outcomes. Continued research, education, and guideline development will further integrate biomarker-driven approaches into routine hospital care, ultimately reducing the burden of malnutrition and metabolic complications in vulnerable populations.